Abstract
Pirazolac is known as a compound having both anti-inflammatory and immunomodulating activities. We studied the effects of Pirazolac on anti-SRBC response in BALB/c mice (female, 7w) and in MRL/Mp-lpr/lpr (MRL/1) mice (male, 20w) with spontaneously occurring autoimmune diseases. In BALB/c mice, Pirazolac enhanced spleen hemolytic plaque forming cell (HPFC) and rosette forming cell (RFC) productions at 3 or 30 mg/kg p.o. On the other hand it suppressed spleen HPFC productions in MRL/l mice at 3 or 30 mg/kg p.o. T cell subsets analysis showed that the effect of Pirazolac in MRL/l mice was based on the increase in suppressor/cytotoxic T cells (Lyt-1-2+) in the spleen cells. To clarify the mechanisms of immunomodulating activities of Pirazolac, the effect of Pirazolac on phagocytosis of peritoneal exudate cells of BALB/c mice was studied using Candida parapsilosis as a target cell. Pirazolac enhanced candidacidal activities at 10-7-10-6M. This result suggests that some part of immunomodulating activities of Pirazolac was due to activation of macrophages.
